Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a new build of the page content. This update reflects an updated release of study documents and related UI elements.SummaryDifference0.0%

- Check9 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a small platform update. No study content or data appears to be affected.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedAdded recruitment status message 'No longer looking for participants' and new user-help sections 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'. Formatting changes include updating the header from 'Intervention / Treatment' to 'Intervention/Treatment' and bumping the revision tag to v3.6.0.SummaryDifference0.2%

- Check31 days agoChange DetectedThe page's Revision label was updated from v3.5.4 to v3.5.5, indicating a small update to the page’s underlying version.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4. This is a minor update to the page's revision history metadata.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page footer/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a site release change without altering the study information presented.SummaryDifference0.0%

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.